SGLT
Sodium-dependent glucose cotransporters
SGLTs (Sodium-dependent glucose cotransporters) are a family of glucose transporters and contribute to glucose reabsorption. The two most well-known members of SGLT family are SGLT1 and SGLT2, which are members of the SLC5A gene family. The two transporters are of primary importance for glucose homeostasis by absorbing glucose from the diet in the small intestine (via SGLT1) and by reabsorbing the filtered glucose in the tubular system of the kidney (primarily SGLT2; to smaller extent via SGLT1); the latter process returns glucose into the blood stream and prevents urinary glucose loss. SGLT1 and SGLT2 have been proposed as a novel therapeutic strategy for diabetes and cardiomyopathy.
SGLT Isoform Specific Products
All Product Categories
-
SGLT Related Products (97)
Related Products (97)
-
SGLT Isoform Comparison
-
Canagliflozin (Standard)
0 ImagesSynonyms: JNJ 28431754 (Standard)Canagliflozin (Standard) is the analytical standard of Canagliflozin. This product is intended for research and analytical applications. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
-
Ertugliflozin-d5
0 ImagesCat. No.: HY-15461SCAS No.: 1298086-22-2Synonyms: PF-04971729-d5Ertugliflozin-d5 is the deuterium labeled Ertugliflozin. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
-
Ipragliflozin (Standard)
0 ImagesSynonyms: ASP1941 (Standard)Ipragliflozin (Standard) is the analytical standard of Ipragliflozin. This product is intended for research and analytical applications. Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent.
-
SGLT2-IN-6
0 ImagesCat. No.: HY-180528SGLT2-IN-6 (Compound 101) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 6.7, and 72 nM respectively. SGLT2-IN-6 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-6 can be used for the study of type 2 diabetes.
-
Remogliflozin etabonate-d7
0 ImagesCat. No.: HY-166548SCAS No.: 1233515-93-9Synonyms: GSK189075-d7Remogliflozin etabonate-d7 (GSK189075-d7) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.
-
Phlorizin (Standard)
0 ImagesPhlorizin (Floridzin) (Standard) is the analytical standard of Phlorizin. This product is intended for research and analytical applications. Phlorizin is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities.
-
TP0438836
0 ImagesCat. No.: HY-124664CAS No.: 957772-01-9TP0438836 (compound 30b) is a SGLT1 inhibitor, with IC50 values of 28 nM and 7 nM for hSGLT1 and hSGLT2, respectively. TP0438836 can be used in diabetes research.
-
Velagliflozin proline (Standard)
0 ImagesCat. No.: HY-109018ARCAS No.: 1539295-26-5Velagliflozin proline (Standard) is the analytical standard of Velagliflozin (proline) (HY-109018A). This product is intended for research and analytical applications. Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.
-
Dapagliflozin-d4
0 ImagesCat. No.: HY-10450S2CAS No.: 1224234-25-6Synonyms: BMS-512148-d4Dapagliflozin-d4 (BMS-512148-d4) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
-
Sergliflozin-A
0 ImagesCat. No.: HY-165438CAS No.: 360775-96-8Sergliflozin-A is a compound used to inhibit type 2 diabetes. It can inhibit glucose transporters in the kidney, competitively inhibit hSGLT1 and hSGLT2, and mutations at different sites have different effects on its inhibitory effect.
-
Empagliflozin-d6
0 ImagesCat. No.: HY-15409S2Synonyms: BI 10773-d6Empagliflozin-d6 (BI 10773-d6) is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
-
galacto-Dapagliflozin
0 ImagesCat. No.: HY-137145CAS No.: 1408245-02-2Galacto-dapagliflozin is a selective inhibitor for hSGLT2 with Ki of 25 nM.
-
Luseogliflozin (Standard)
0 ImagesCat. No.: HY-10449RCAS No.: 898537-18-3Synonyms: TS 071 (Standard)Luseogliflozin (Standard) is the analytical standard of Luseogliflozin (HY-10449). This product is intended for research and analytical applications. Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes.
-
SGLT2-IN-4
0 ImagesCat. No.: HY-180201CAS No.: 1061314-92-8SGLT2-IN-4 (Compound 1) is a selective and orally active sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor. SGLT2-IN-4 can increase the proportion of protein α-helix and enhance the stability of the SGLT2-D201A mutant. SGLT2-IN-4 can be used for the research of type 2 diabetes.
-
Velagliflozin (Standard)
0 ImagesCat. No.: HY-109018RCAS No.: 946525-65-1Velagliflozin (Standard) is the analytical standard of Velagliflozin (HY-109018). This product is intended for research and analytical applications. Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
-
Olorigliflozin
0 ImagesCat. No.: HY-168989CAS No.: 2035989-50-3Olorigliflozin is a sodium glucose co-transporter inhibitor with anti-hyperglycemic effects.
